Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1998-11-25
2002-09-17
Fredman, Jeffrey (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S023100, C536S024310
Reexamination Certificate
active
06451524
ABSTRACT:
FIELD OF THE INVENTION
The present invention is directed to methods of identifying target nucleic acid sequences which are predictive of disease states or biological conditions in cells containing the nucleic acid sequence.
BACKGROUND OF THE INVENTION
Recent advances in genomics, molecular biology, and structural biology have highlighted how RNA molecules participate in or control many of the events required to express proteins in cells. Rather than function as simple intermediaries, RNA molecules actively regulate their own transcription from DNA, splice and edit mRNA molecules and tRNA molecules, synthesize peptide bonds in the ribosome, catalyze the migration of nascent proteins to the cell membrane, and provide fine control over the rate of translation of messages. RNA molecules can adopt a variety of unique structural motifs, which provide the framework required to perform these functions.
The many functions of RNA molecules has also solidified their importance as therapeutic drug and diagnostic targets. Indeed, many investigators are pursuing mRNA transcripts and proteins produced therefrom that are expressed at different levels in cancer vs. normal cells in order to develop therapeutic and/or diagnostic compounds which modulate the cancer-causing mRNA transcript or protein. Indeed, 500 transcripts have been reported to be expressed at significantly different levels (15-fold on average) in normal vs. gastrointestinal tumor cells. Zhang, et al.,
Science
, 1997, 276, 1268-72. Many genes have as many as 10-20 alternative transcript forms that, in some cases, have been associated with a cancer phenotype. For example in cancerous cells, transcription of the mdm2 gene is initiated at a distinct site not used in normal cells. Landers, et al.,
Cancer Res
., 1997, 57, 3562-3568, incorporated herein by reference in its entirety. In the Bcl-x mRNA, alternatively spliced forms of the transcript result in dramatically different cell behavior and sensitivity to chemotherapeutic drugs. Kuhl, et al.,
Br. J. Cancer
, 1997, 75, 268-274, which is incorporated herein by reference in its entirety.
A universal technology platform to attack multiple forms of cancer has widely been believed to be impossible due to the heterogeneous nature of cancer. Thus, traditional cancer therapeutics has focused on individual cancer pathways and modulation of individual proteins and/or mRNA transcripts associated with the suspected causative pathway of the disease state. An unconventional, broadly applicable approach to cancer diagnosis and treatment, however is greatly desired. Accordingly, the present invention provides the means to identify distinguishing features of types of cancer coupled with a common molecular mechanism to diagnose and selectively destroy the cancer cells or other cells associated with a disease state or biological condition. It is a principal object of the invention to identify a target nucleic acid sequence which is predictive of a disease state or biological condition in cells containing the nucleic acid sequence.
SUMMARY OF THE INVENTION
The present invention is directed to methods of identifying target nucleic acid sequences which are predictive of preselected disease states or biological conditions in cells containing the nucleic acid sequence. Members of a set of mRNA molecules from a common gene, but containing different sequences and structures, are compared. The gene is predictive of the disease state or biological condition in cells containing the gene. At least one molecular interaction site from among those present in the members of the set are identified. The molecular interaction site is present in cells likely to have the disease state or biological condition. At least one nucleic acid sequence from the molecular interaction site is ascertained.
REFERENCES:
patent: 5582972 (1996-12-01), Lima et al.
patent: 5866698 (1999-02-01), Ecker et al.
patent: 5885834 (1999-03-01), Epstein
patent: 5962673 (1999-10-01), Monia et al.
patent: 5977311 (1999-11-01), Nandabalan et al.
patent: 6221587 (2001-04-01), Ecker et al.
Klaff et al. “RNA structure and the regulation of gene expression” Plant Molecular Biology, vol. 32, pp. 89-106, Oct. 1996.*
Dandekar et al. “Finding the hairpin in the haystack: serching for RNA motifs” Trends in Genetic, vol. 11, No. 2, pp. 45-50, Feb. 1995.*
Balvay et al. “Pre-mRNA Secondary Structure and the regulation of Splicing” BioEssays, vol. 15, No. 3, pp. 165-169, Mar. 1993.*
Harries et al. “Strategies for targeted gene therapy” Trends in Genetics, vol. 12, No. 10, pp. 400-405, Oct. 1996.*
Trends Genetics, “The G-tetrad in antisense targeting” Trends in Genetics, vol. 12, No. 8., pp. 90-91, Aug. 1996.*
Marshall et al “Gene therapy's growing pains” Science, vol. 269, pp. 1050-1055, Aug. 1995.*
Franch et al. “Programmed Cell Death by hok/sok of Plasmid R1: Processing at the hok mRNA 3' end triggers structurall rearrangemetns that allow translation and antisense RNA binding” JMB, vol. 273, No. 1, pp. 38-51, Oct. 17, 1997.*
Franch et al. “Programmed Cell Death by hok/sok of Plasmid R1 copuled nucleotide covariations reveal a phylogenetically conserved folding pathway in the hok family of mRNAs” JMB, vol. 273, No. 1, pp. 26-37, Oct. 17, 1997.*
Benson et al., “GenBank”,Nucl. Acids Res.,1998, 26(1), 1-7.
Brown, J.W., “Phylogenetic analysis of RNA structure on the Macintosh computer”,CABIOS Commun.,1991, 7(3), 391-393.
Edwalds-Gilbert, “Alternative poly(A) site selection in complex transcription units: means to an end?”,Nucl. Acids Res.,1997, 25(13), 2547-2561.
Gautheret et al., “Identification of Base-triples in RNA using Comparative Sequence Analysis,”J. Mol. Biol.,1995, 248, 27-43.
Gautheret et al., “G U base pairing motifs in ribosomal RNA”, RNA, 1995, 1, 807-814.
Gautheret et al., “Inferring the conformation of RNA base pairs and triples from patterns of sequence variation”,Nucl. Acids Res.,1997, 25(8), 1559-1564.
Gautheret, “Alternate to Polyadenylation in Human mRNAs: A Large-Scale Analysis by EST Clustering”,Genome Res.,1998, 8, 524-530.
Gutell, “Collection of small subunit (16S-and 16S-like) ribosomal RNA structures: 1994”,Nucl. Acids Res.,1994, 22(17), 3502-3507.
Gutell, “Collection of small subunit (16S-and 16S-like) ribosomal RNA structures”,Nucl. Acids Res.,1993, 21(13), 3051-3054.
Gutell, “A compilation of large subunit (23S and 23S-like) ribosomal RNA structures: 1993”,Nucl. Acids Res.,1993, 21(13), 3055-3074.
Gutell et al., “Comparative Sequence Analysis of Experiments Performed During Evolution”, in Ribosomal RNA Group I Introns, Green (ed.), Austin: Landes, 1996, Ch. 2, 15-33.
Kuhl et al., “Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia”,Br. J. Cancer,1997, 75(2), 268-274.
Laferriere et al., “An RNA pattern matching program with enhanced performance and portability”,Comput. Appl. Biosci.,1994, 10(2), 211-212.
Landers et al., “Transitional Enhancement of mdm2 Oncogene Expression in Human Tumor Cells Containing a Stabilized Wild-Type p53 Protein”,Cancer Res.,1997, 57, 3562-3568.
Lodmell et al., “Genetic and comparative analyses reveal an alternative secondary structure in the region of nt 912Escherichia coli16S rRNA”,Proc. Natl. Acad. Sci. USA,1995, 92, 10555-10559.
Müller-Pillasch et al., “Cloning of Novel Transcripts of the Human Guanine-Nucleotide-Exchange Factor Mss4: In Siu Chromosomal Mapping and Expression in Pancreatic Cancer”,Genomics,1987, 46, 389-396.
Scott et al., “A Truncated Intracellular HER2
eu Receptor Produced by Alternative RNA Processing Affects Growth of Human Carcinoma Cells”,Mol. Cell Biol.,1993, 13(4), 2247-2257.
Sutton et al., “TIGR Assembler: A New Tood for Assembling Large Shotgun Sequencing Projects”,Genome Science&Tech.,1995, 1(1), 9-19.
Thompson et al., “CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice”,Nucl. Acids Res.,1994, 22(22), 4673-4680.
Woese et al., “Evidence for several higher order structural elements in ribosomal
Fredman Jeffrey
Goldberg Jeanine
ISIS Pharmaceuticals Inc.
Woodcock & Washburn LLP
LandOfFree
Identification of disease predictive nucleic acids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification of disease predictive nucleic acids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of disease predictive nucleic acids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2844513